{"groups":[{"description":"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.\n\nAge group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG000","title":"Adipocytic Tumors Group"},{"description":"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.\n\nAge group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG001","title":"Vascular Tumors Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG002","title":"Undifferentiated Pleomorphic Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG003","title":"Synovial Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG004","title":"Osteosarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG005","title":"Other Sarcomas Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG006","title":"Alveolar Soft-part Sarcoma Group"},{"description":"Age group ≥12 and \\<18: Dosages of study drugs to be determined (TBD).\n\nAge group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.\n\nCombination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses.\n\nDurvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).\n\nTremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.","id":"FG007","title":"Chordomas Group"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"9"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"1"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Pregnancy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"10"},{"groupId":"FG007","numSubjects":"5"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}